Erythropoietin receptor (EPO-R)

Class

Erythropoiesis-stimulating agent (ESA) -- biosimilar to darbepoetin alfa

Pathway

Erythropoiesis / anemia of CKD

The erythropoietin receptor (EPO-R) sits on the surface of erythroid progenitor cells in the bone marrow, the precursors that mature into red blood cells. Its natural ligand, erythropoietin (EPO), is a hormone produced mainly by the kidney in response to low oxygen levels. When EPO binds EPO-R, it triggers survival and proliferation signals that allow these progenitors to differentiate into mature red blood cells rather than undergo programmed cell death. In chronic kidney disease, damaged kidneys produce insufficient endogenous EPO, leading to anemia because red cell production cannot keep pace with normal turnover. Erythropoiesis-stimulating agents (ESAs) are engineered to bind and activate EPO-R in the same way as the natural hormone, restoring adequate signaling and stimulating red blood cell production. Variants of these agents differ in how long they remain active in circulation, achieved through modifications such as additional sugar chains, polyethylene glycol (PEG) attachment, or use of peptide mimetics rather than the native protein sequence, which can reduce how often they need to be given. This mechanism is broadly relevant wherever anemia arises from inadequate erythropoietin production or blunted marrow responsiveness, with anemia of chronic kidney disease being the principal setting in which EPO-R agonism is used therapeutically.